International Patient Organisation for Primary Immunodeficiencies

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 16 Sep 2024
How to read and use this data card.
Download this datacard

Overview

Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

3 Fte (4)

Lobbyists with EP accreditation

0

High-level Commission meetings

2

Lobbying Costs over the years

  • Info

    International Patient Organisation for Primary Immunodeficiencies   (IPOPI)

    EU Transparency Register

    379847424451-15 First registered on 11 Nov 2016

    Goals / Remit

    IPOPI is the Association of national patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency patients worldwide through global collaboration.
    IPOPI’s various projects and programmes are geared towards the 4 following strategic objectives:
    1. To promote early diagnosis & ensure optimal access to care
    2. To develop, strengthen and support National Member Organisation
    3. To raise PID awareness globally
    4. To stimulate stakeholder collaboration

    Main EU files targeted

    Blood legislation, rare diseases, orphan medicinal product, advanced therapeutic medicinal products, European Reference Networks, crossborder healthcare directive, equal access to care, patients' rights, research and innovation, patient registries, European health data space, European health union, pharmaceutical strategy.

    Address

    Head Office
    Avenue Louise/ Louizalaan 65, Bte 11
    Brussels 1050
    BELGIUM
    EU Office
    Avenue Louise/ Louizalaan 65, Bte 11
    Brussels 1050
    BELGIUM

    Website

  • People

    Total lobbyists declared

    4

    Employment timeLobbyists
    100%2
    50%2

    Lobbyists (Full time equivalent)

    3

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 15 Nov 2024

    Name Start date End Date
    Solis LEIRE 30 Aug 2023 30 Aug 2024
    Johan PREVOT 14 Feb 2024 04 Oct 2024

    Complementary Information

    IPOPI has 9 FTE staff members, 0.50 FTE and 0.25 FTE staff members. IPOPI also counts with the contribution and work of its Board members and Medical Advisory Panel. IPOPI works with consultants in the area of public affairs and event management.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    IPOPI is a founding member of the Platform of Plasma Protein Users (PLUS), of Screen4Rare, and a member of the following organisations: Eurordis, European Patients’ Forum (EPF), Health First Europe and Rare Disease International. IPOPI also participates in ERN RITA.

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year

    2,446,713€

    Major funding types in closed year

    Donations, Grants, Member's contributions, Other

    Funding types "other" information

    NMO assessments: 6 450 € Corporate donations: 1 571 424 € Other donations: 24 735 € IPIC: 468 498€ Volunteer time: 375 606 €

    Major contributions in closed year

    TypeNameAmount
    Contribution Grifols 303,375€
    Contribution CSL Behring 211,125€
    Contribution Volunteer work 375,606€
    Contribution Takeda 302,637€

    Other financial info

    IPOPI accepts corporate sponsorship as long as sponsors accept the Corporate Relations Guiding Principles, that are available on the website: https://ipopi.org/partners/corporate-partners/

    Aside from IPOPI’s own Code of Conduct, representatives of the organisation at the EMA must complete and sign the EMA’s Conflict of Interest rules.

    IPOPI’s accounts are audited by an external auditor and approved by our members during the Annual General Assembly.

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    Unofficial groupings

    Communication activities

    IPOPI develops advocacy campaigns at European and national level, PID Forums at the European Parliament, etc with the objective of advocating towards policy makers on the different policies and dossiers that are of relevance to patients with primary immunodeficiencies.
    IPOPI also engages, through Screen4Rare (partnership with the International Neonatal Screening Society and the European Society for Immunodeficiencies) on activities that aim at informing decision makers on newborn screening for treatable rare disorders.

    Other activities

    None declared

  • Meetings

    Meetings

    2 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

Download this datacard